Tyrosine Kinases
Jak2 Mutant Stable Cell Lines
Unlock the power of precise JAK-STAT pathway analysis with our Ba/F3 cell lines overexpressing human JAK2 cell lines.
Signosis offers a comprehensive portfolio of stable cell lines and assay tools for studying JAK2 signaling pathways, drug discovery, and targeted therapies. Whether you need standard models or specialized mutations, our platform is designed to support your exact research requirements.
While the V617F mutation is a critical driver in myeloproliferative neoplasms (MPNs), effective research and drug screening require examining the entire spectrum of JAK2 alterations. In addition to V617F, we offer other key JAK2 mutations, including K539L, R683G, T875N, and more.
We can also offer or custom generate any JAK2 mutation of your choice. If a specific mutant is not currently in our ready-to-ship catalog, we can rapidly engineer custom stable cell lines to fit your needs. Please contact us at info@signosisinc.com for more information.
Proven Generation & Validation
Comprehensive Mutation Coverage
Our cell lines were generated using a human JAK2 lentiviral transfer vector, co-expressing GFP, allowing for highly efficient packaging, integration, and selection via fluorescent visualization. Cell lines that also express EPOR were sequentially transduced with an EPOR lentiviral transfer vector. Clones are established through GFP and Western blotting using JAK specific antibodies. Clones that also express EPOR were further selected through IL-3 withdrawal, confirming autonomous signaling and robust receptor cooperation.
The Role of EPOR in JAK2 Signaling
The Erythropoietin Receptor (EPOR) plays a vital physiological role in erythropoiesis (red blood cell production) and is closely intertwined with JAK2 signaling dynamics. Mutant JAK2 constitutively activates downstream signaling pathways (such as STAT, MAPK, and PI3K) often through association with cytokine receptors like EPOR, driving disease phenotypes. This association also allows Ba/F3 cells to become IL-3 independent.
Studying JAK2 mutants in the presence or absence of EPOR helps researchers dissect receptor-dependent versus receptor-independent signaling and assess the efficacy of targeted therapeutics in different cellular contexts.
Benefits
Lentiviral Transduction
Engineered using efficient lentiviral transfer vectors, ensuring stable, permanent genomic integration and uniform, long-term expression of JAK2 variants and EPOR.
Double Selection
Single clones are selected with GFP and hygromycin.
Comprehensive Validation
The selected clones have been validated with PCR-sequencing and Western blot analysis.
Functional Analysis
Proliferation tests have been performed on the cell lines with their corresponding inhibitors.
Products
Brand | Name | SKU | Formatted Price |
|---|---|---|---|
K539L + EPOR | Jak2 K539L + EPOR expressing Ba/F3 Cell Line (2 vials) | SL-0203 | $5,000.00 |
K539L | Jak2 K539L Expressing Ba/F3 Cell Line (2 vials) | SL-0204 | $3,870.00 |
R683G + EPOR | Jak2 R683G + EPOR expressing Ba/F3 Cell Line (2 vials) | SL-0205 | $5,000.00 |
R683G | Jak2 R683G Expressing Ba/F3 Cell Line (2 vials) | SL-0206 | $3,870.00 |
T875N + EPOR | Jak2 T875N + EPOR expressing Ba/F3 Cell Line (2 vials) | SL-0207 | $5,000.00 |
T875N | Jak2 T875N Expressing Ba/F3 Cell Line (2 vials) | SL-0208 | $3,870.00 |
V617F + EPOR | Jak2 V617F + EPOR expressing Ba/F3 Cell Line (2 vials) | SL-0202 | $5,000.00 |
V617F | Jak2 V617F Expressing Ba/F3 Cell Line (2 vials) | SL-0201 | $3,870.00 |
WT + EPOR | Jak2 WT + EPOR Expressing Ba/F3 Cell Line (2 vials) | SL-0200E | $3,870.00 |
WT | Jak2 WT Expressing Ba/F3 Cell Line (2 vials) | SL-0200 | $3,870.00 |